Merck & Co Inc Shares Face Pressure from Trump's Pricing Initiative
President Trump's 'Most Favored Nation' pricing initiative aims to reduce prescription drug costs nationwide, potentially impacting healthcare companies like Merck & Co Inc (NYSE: MRK). The plan promises substantial savings for Medicaid recipients and government budgets.
Merck currently offers a 2.31% dividend yield but carries a high payout ratio of 1.05, raising questions about the sustainability of its dividend despite a moderate 3-year dividend growth rate of 5.4%. The stock is modestly overvalued by 21.7% relative to its GF Value™ of $120.15.
The company holds a solid GF Score™ of 76/100, reflecting balanced financial strength and profitability, though momentum remains a relative weakness. Insider activity reveals no recent purchases and $71.4 million in insider selling over the past 12 months, while 27 top gurus hold MRK shares, with 16 trimming and 8 adding positions recently.